If programmable CRISPR protocols allow a lab to go from patient biopsy to edited pluripotent line and differentiated cells in a matter of weeks, those oversight mechanisms will need to adapt so they ...
In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...
Crispr Therapeutics, in collaboration with Vertex, pioneered the first CRISPR-based gene therapy, Casgevy, with regulatory approval in multiple countries, poised for strong revenue growth from Q4 2024 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results